Pricing Log in Create free account
Friday 6 November 2026 Export AKBA’s income statement to Excel — free account

Akebia Therapeutics, Inc.

AKBA Healthcare Drug Manufacturers Specialty & Generic

Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024.

Revenue
−37.2%
EPS
−2,600.0%
Free cash flow
−94.2%
Total debt
+5.52%

Quarter to September 2026, against a year earlier

0.43 0.26 −37.68%
Market cap
$117.9M
P/E
0.0×
Fwd P/E
−4.9×
Dividend yield
—
F-score
7/9
Altman Z
−4.42
Beneish M
−3.16
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.09
Sold, $m 0.96
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 1 — — — — — — — —
Sell — — 6 — — — 1 — — — — —
Insider Ownership 2.63%

Capital & Financial Ratios $m

Size
Market Cap 117.91
Revenue ttm 197.20
Net income ttm (44.56)
Free cash flow ttm 13.86
Net debt Q (108.98)
Valuation
P/E 0.00
Forward P/E (4.93) (negative: loss-making)
Price / sales 0.60
Forward P/S Powerpack
Price / FCF 8.59
Price / book 5.84
Financial health
Current ratio Q 1.36
Debt / equity Q 2.47 (above 2: weak)
Interest coverage Q (3.65)
Growth
Revenue growth Q −37.20% (below 0%: shrinking)
Operating income growth Q −357.63% (below 0%: shrinking)
EPS, this year −600.00% (below 0%: weak)
EPS, next year A −122.62% (below 0%: weak)
Revenue, next year A −16.26% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +55.04% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.1×, against a ten-year median of 1.3×; over the ten years it ranged from 0.1× in 2026 to 4.8× in 2020.
P/S against its own 10 years 11.96%
10-year low 10-year high
P/B against its own 10 years 70.27%
10-year low 10-year high
EV/Sales against its own 10 years 0.09%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 43 52 185 159
Receivables 39 34 47 36
Inventory 16 16 16 19
Other — — — —
118 114 253 221
2023 2024 2025 Q'26
Payables 15 15 21 8
ST’ Debt 18 — — 37
Other — 2 17 10
100 81 163 162

Compound Annual Growth %

10y 5y 3y
Sales — (4.33%) (6.88%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (12.98%) (33.33%) 84.06%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.03 Actual −0.02

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.00 0.00 Met by 0.00
Q4 FY25 −0.03 −0.05 Miss by 0.02
Q1 FY26 −0.01 −0.03 Miss by 0.02
Q2 FY26 −0.03 −0.02 Beat by 0.01
Q3 FY26 −0.03 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.03) (0.03) (0.05) — —
’25 0.03 0.00 0.00 (0.05) (0.02)
’24 (0.09) (0.04) (0.10) (0.10) (0.33)
’23 (0.14) (0.06) (0.08) 0.00 (0.28)
’22 (0.35) 0.15 (0.28) (0.04) (0.51)
’21 (0.45) (0.51) (0.34) (0.40) (1.70)
’20 (0.47) (1.28) (0.42) (0.60) (2.77)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 54 49 37 — —
’25 57 62 59 58 236
’24 33 44 37 46 160
’23 40 56 42 56 195
’22 62 126 49 56 292
’21 52 53 49 58 212
’20 88 90 60 56 295
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (21) 4 2 — —
’25 (14) 22 28 31 68
’24 (19) (10) (7) (4) (41)
’23 (18) 4 (7) (2) (23)
’22 (22) (31) 34 (55) (73)
’21 (71) (63) (56) (63) (253)
’20 (90) 37 (27) (31) (110)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (21) 2 2 — —
’25 (13) 22 28 31 68
’24 (19) (10) (7) (4) (41)
’23 (18) 4 (7) (2) (23)
’22 (22) (31) 34 (55) (73)
’21 (71) (63) (56) (63) (253)
’20 (90) 37 (27) (31) (111)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 181 208 335 295 212 292 195 160 236 197 +75.0% 198 133 165 (11.3%)
Gross margin, % 100.00 100.00 96.26 56.62 38.21 28.81 70.74 61.90 60.56 83.29 78.90 (16.7) pt
EBT (136) (74) (172) (286) (385) (282) (94) (52) (69) (4) (43) (32.9%)
EBT margin, % (8,843.45) (40.65) (82.76) (85.46) (130.61) (133.25) (32.22) (26.68) (43.33) (1.58) (21.90) +8,841.9 pt
Net income (136) (74) (144) (280) (385) (282) (94) (52) (69) (5) (45) (30.2%)
Per share, $
Per share, $ Revenue 0.04 4.17 3.58 2.83 2.13 1.28 1.60 1.04 0.76 0.92 0.71 +41.4%
Earnings (3.60) (1.77) (2.47) (2.36) (2.77) (1.70) (0.51) (0.28) (0.33) (0.02) (0.16) (43.8%)
Cash flow 1.54 (1.29) (1.68) (2.17) (0.80) (1.52) (0.40) (0.12) (0.19) 0.26 0.06 (17.8%)
Capex (0.07) (0.04) (0.03) (0.06) 0.00 0.00 0.00 0.00 0.00 0.00 (0.01) (42.3%)
Free cash flow 1.46 (1.33) (1.71) (2.23) (0.80) (1.52) (0.40) (0.12) (0.19) 0.26 0.05 (17.3%)
Book value 1.81 2.82 10.96 3.33 1.79 0.45 0.03 (0.16) (0.23) 0.13 0.07 (25.6%)
Shares, m 38 44 58 118 138 166 183 187 211 257 268 +23.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 3.59 1.54 2.23 1.32 1.77 0.39 1.22 2.50 1.75 0.60 1.6
P/B 5.81 5.31 0.50 1.90 1.57 5.07 21.67 0.00 0.00 12.70 5.84 5.5
EV/Sales 0.00 1.84 1.11 2.03 0.88 1.94 0.30 1.18 2.53 1.25 0.05 1.3
EV/FCF 2.46 (5.77) (2.33) (2.58) (2.30) (1.62) (1.21) (9.78) (9.96) 4.35 0.73 (2.9)
Cash, $m
Cash, $m Operating cash flow 58 (56) (97) (257) (110) (253) (73) (23) (41) 68 16 +1.8%
Capex (3) (2) (2) (7) 0 0 0 — 0 0 (2) (29.2%)
Free cash flow 55 (58) (99) (264) (111) (253) (73) (23) (41) 68 14 +2.3%
Balance, $m
Balance, $m Working capital 182 217 203 101 184 10 56 18 33 90 58 (7.5%)
Net debt (260) (318) (90) (67) (127) 35 (24) (8) (13) (137) (109) (6.9%)
Shareholders’ equity 68 123 636 395 248 74 5 (31) (49) 33 20 (7.9%)
Returns, %
Returns, % ROA (61.26) (22.17) (21.10) (31.64) (54.38) (48.07) (21.28) (17.37) (30.02) (1.79) (12.62) +59.5 pt
ROIC 0.00 0.00 (20.38) (54.53) (196.30) (152.01) 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (136.35) (77.27) (37.86) (54.27) (119.82) (175.37) (237.83) 409.60 174.03 64.49 (143.83) +200.8 pt
People
People Employees 90 114 325 360 380 426 205 167 181 194 — +8.9%
Revenue/emp, $m 0.02 1.59 0.64 0.93 0.78 0.50 1.43 1.17 0.88 1.22 — +60.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Akebia Therapeutics, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ANIK Anika Therapeutics Inc. $258.7M — (loss-making) 599× +15.56% (above 0%: growing) n/m +61.58% (above 0%: growing) 65.15% 9.06% Compare
BIOA BioAge Labs, Inc. $254.3M — (loss-making) — (loss-making) −85.49% (below 0%: shrinking) n/m −92.81% (below 0%: shrinking) 100.00% (12,554.03%) Compare
LFCR Lifecore Biomedical, Inc. $242.6M — (loss-making) — (loss-making) −18.60% (below 0%: shrinking) n/m +27,684.00% (above 0%: growing) 26.96% (3.53%) Compare
SIGA Siga Technologies Inc. $213.4M — (loss-making) 60.8× −49.45% (below 0%: shrinking) −66.00% (below 0%: shrinking) −75.95% (below 0%: shrinking) 57.17% 33.91% Compare
ADCT ADC Therapeutics SA $209.4M — (loss-making) — (loss-making) +2.17% (above 0%: growing) n/m +50.98% (above 0%: growing) 87.80% (132.03%) Compare
GLAS Glass House Brands Inc. $172.7M — (loss-making) — (loss-making) −1.24% (below 0%: shrinking) n/m −123.36% (below 0%: shrinking) 33.54% (6.37%) Compare
OGI Organigram Global Inc. $131.1M 2.0× 1.6× +49.28% (above 0%: growing) n/m −192.32% (below 0%: shrinking) 39.16% 5.04% Compare
DERM Journey Medical Corporation $121.4M — (loss-making) — (loss-making) +23.33% (above 0%: growing) n/m −84.08% (below 0%: shrinking) 66.81% 2.46% Compare
AKBA Akebia Therapeutics, Inc. $117.9M — (loss-making) — (loss-making) −37.20% (below 0%: shrinking) n/m −94.20% (below 0%: shrinking) 82.76% (31.06%)
Median of peers $211.4M — 60.8× +0.47% — −80.01% 61.16% (0.53%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 28 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 5.65m 4.22m 57.50
2024 4.26m 5.57m 67.86
2023 2.78m 4.50m 44.29
2022 3.07m 707.64k 20.61
2021 3.13m 2.42m 80.71

Ownership

Directors and executive officers, together 4.30%
BlackRock, Inc.50 Hudson YardsNew York, NY 7.20%
State Street CorporationOne Congress Street, Suite 5.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Akebia Therapeutics, Inc. (AKBA) Latest News

6 Nov

Impact 3 · · GuruFocus.com transcript

5 Nov

Impact 3 · · MarketBeat transcript
Impact 3 · · Zacks
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

26 Oct

Impact 4 · · GlobeNewswire

7 Oct

Impact 3 · · GlobeNewswire

6 Oct

Impact 4 · · GlobeNewswire

14 Sep

Impact 3 ·

6 Aug

Impact 4 · transcript

5 Aug

Impact 3 ·
Impact 3 · · MarketBeat transcript
Impact 3 ·

3 Aug

Impact 3 ·

30 Jun

Impact 4 ·
Impact 4 ·

10 Jun

Impact 3 · · GlobeNewswire

4 Jun

Impact 4 · · MarketBeat

11 May

Impact 3 · · Simply Wall St.

8 May

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby transcript

7 May

Impact 3 · · MarketBeat
Impact 3 · · GlobeNewswire

4 May

Impact 4 · · GlobeNewswire

6 Apr

Impact 4 · · Simply Wall St.

2 Apr

Impact 4 · · MarketBeat

19 Mar

Impact 3 · · GlobeNewswire

9 Mar

Impact 4 · · MarketBeat

8 Mar

Impact 4 · · Simply Wall St.

27 Feb

Impact 3 · · Moby
stockrow.com/AKBA · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com